NewAmsterdam Pharma Company N.V. Warrant financials
$11.40−0.78%
Close Sep 24, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 |
|---|---|---|---|---|
| Revenue | $22.5M | $45.6M | $14.1M | $102.7M |
| Gross profit | $22.5M | $45.6M | $14.1M | $102.7M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$225.7M | -$176.3M | -$183.0M | -$3.6M |
| Net income | -$203.8M | -$241.6M | -$176.9M | -$22.6M |
| Net margin | −905.7% | −530.3% | −1255.8% | −22.0% |
| Diluted EPS | $-1.72 | $-2.66 | $-2.15 | $-1.19 |
| EBITDA | -$225.5M | -$176.2M | -$182.9M | -$3.5M |
| Operating cash flow | -$147.8M | -$158.6M | -$141.2M | $10.7M |
| Free cash flow | -$148.0M | -$159.2M | -$141.2M | $10.4M |
| Diluted shares | 118.4M | 94.4M | 82.2M | 19.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Cash & equivalents | $490.0M | $771.7M | $340.4M | $470.4M |
| Short-term investments | $146.2M | $62.4M | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $769.3M | $864.6M | $347.1M | $570.2M |
| Total liabilities | $85.9M | $107.1M | $58.7M | $50.5M |
| Shareholders' equity | $683.4M | $757.5M | $288.4M | $519.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology